Evidence map›Paper›PMID 31752566›Full record

Trial reportDrug delivery2019

Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients.

Maha K A Khalifa, Hoda A Salem, Seham M Shawky, Heba A Eassa, Asmaa M Elaidy

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Investigating the Impact of OptimizedInternational journal of nanomedicine · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Maha K A KhalifaDepartment of Pharmaceutics and industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt.ORCID http://orcid.org/0000-0002-8053-8059
Hoda A SalemDepartment of Clinical Pharmacy, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt.
Seham M ShawkyDepartment of Pharmaceutics and industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt.
Heba A EassaDepartment of Pharmaceutics and industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt.
Asmaa M ElaidyDepartment of Psychiatry, Faculty of Medicine for girls, Al-Azhar University, Nasr City, Egypt.
Al-Azhar University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this work is to develop self-nano emulsifying drug delivery system (SNEDDS) to enhance the oral bioavailability of zaleplon (Zal) as a poorly water-soluble drug. Moreover, the bioavailability and the effect on the quality of sleep among a sample of psychiatric patients is to be assessed. D-optimal mixture design was used for optimization. Optimized SNEDDS formulation was evaluated for droplet size, transmission electron microscope (TEM) and in-vitro dissolution test. Zal bioavailability was evaluated by determining its serum concentration and pharmacokinetic parameters in 8 patients after oral administration. Effect on sleep quality was assessed among 40 psychiatric patients. Patients' sleep quality was assessed in 40 psychiatric patients before and after medication using the Arabic version of the Pittsburgh Sleep Quality Index (PSQI). Zal- SNEDDS appeared as nano-sized spherical vesicles. Moreover, Zal was completely dissolved from optimized formulation after 45 min indicating improved dissolution rate. Zal-SNEDDS showed significantly higher

Indexed as

AcetamidesAdministration, OralAdultBiological AvailabilityCross-Sectional StudiesDrug CarriersEmulsionsFemaleHumansHypnotics and SedativesMaleMental DisordersMiddle AgedNanoparticlesPyrimidinesSleep Initiation and Maintenance DisordersAcetamidesDrug CarriersEmulsionsHypnotics and SedativesPyrimidineszaleplonbioavailabilitypoorly water-soluble drug and quality of sleepself-nano emulsifying drug delivery system (SNEDDS)Zaleplon

Identifiers

PMID31752566
PMCPMC6882476
OpenAlexW2990251155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.